Skip to main content

Table 3 Multivariate Analyses of OS and BCSM in original samples and matched samples

From: Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

Variable original samples matched samples
  HR for 95%CI P HR for 95%CI P HR for 95%CI P HR for 95%CI P
OS BCSM OS BCSM
Age (years) < 40 Reference    Reference    Reference    Reference   
40–49 0.95 0.22–4.08 0.949 0.66 0.14–3.01 0.597 0.84 0.19–3.70 0.814 0.86 0.19–3.96 0.857
50–59 0.55 0.14–2.27 0.410 1.04 0.24–4.39 0.957 0.49 0.12–2.06 0.333 1.07 0.24–4.65 0.923
60–69 0.36 0.09–1.44 0.147 0.83 0.19–3.53 0.805 0.29 0.07–1.20 0.087 0.91 0.20–4.05 0.903
70–79 0.16 0.04–0.63 0.009 2.24 0.53–9.39 0.268 0.19 0.05–0.81 0.025 1.43 0.30–6.82 0.650
Race Black Reference    Reference    Reference    Reference   
White 1.61 1.21–2.15 0.001 0.61 0.36–1.04 0.075 2.32 1.50–3.60 0.001 0.39 0.20–0.75 0.005
Others 1.64 1.01–2.68 0.047 0.54 0.21–1.40 0.211 2.54 1.10–5.90 0.030 0.25 0.05–1.12 0.071
Tumor (Ic vs Ib) 0.84 0.67–1.04 0.111 1.39 0.88–2.20 0.153 0.87 0.56–1.34 0.524 1.50 0.70–3.22 0.290
LN (N1 vs N0) 0.61 0.48–0.78 0.001 2.11 1.37–3.24 0.001 0.76 0.54–1.07 0.112 1.66 0.96–2.88 0.069
Grade I Reference    Reference    Reference    Reference   
II 0.96 0.78–1.18 0.679 1.35 0.88–2.07 0.158 0.84 0.56–1.25 0.384 1.38 0.71–2.66 0.332
III 0.85 0.57–1.26 0.418 1.69 0.84–3.42 0.141 0.66 0.37–1.17 0.156 1.35 0.50–3.64 0.552
Surgery No surgery Reference    Reference    Reference    Reference   
BCS 7.19 4.91–10.53 0.001 0.06 0.03–0.12 0.001 10.84 5.39–21.80 0.001 0.06 0.02–0.17 0.001
Mastectomy 7.39 5.24–10.41 0.001 0.06 0.03–0.10 0.001 8.11 4.51–14.58 0.001 0.08 0.03–0.19 0.001
Chemotherapy (Yes vs No) 0.82 0.62–1.09 0.172 2.33 1.47–3.67 0.001 0.90 0.65–1.26 0.553 2.41 1.32–4.39 0.004
Radiotherapy (Yes vs No) 2.07 1.58–2.70 0.001 0.48 0.29–0.82 0.007 1.41 0.89–2.23 0.142 0.66 0.32–1.34 0.253